Abstract
Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.
| Original language | English |
|---|---|
| Pages (from-to) | 685-690 |
| Number of pages | 6 |
| Journal | Hepato-Gastroenterology |
| Volume | 44 |
| Issue number | 15 |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- Anemia
- Blood transfusion
- Cancer
- Cost/benefit analysis
- Erythropoiesis
- Erythropoietin
- Surgery
ASJC Scopus subject areas
- Gastroenterology
Cite this
Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery. / Braga, M.; Gianotti, L.; Gentilini, O.; Vignali, A.; Di Carlo, V.
In: Hepato-Gastroenterology, Vol. 44, No. 15, 1997, p. 685-690.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery
AU - Braga, M.
AU - Gianotti, L.
AU - Gentilini, O.
AU - Vignali, A.
AU - Di Carlo, V.
PY - 1997
Y1 - 1997
N2 - Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.
AB - Background/Aims: This trial was designed to quantify the production of new red blood cells (RBCs) after treatment with recombinant human erythropoietin (rHuEPO). Materials and Method: Twenty anemic patients with gastric or colorectal cancer were prospectively studied. The control group (n = 10) underwent surgery without delay. The experimental group (n = 10) received treatment with 500 U/kg of r-HuEPO divided in three doses which were administrated as follows: 300 U/kg 12 days before surgery and 100 U/kg 4 and 8 days later. Results: RBC gain was 210 ± 75 mL in the experimental group which received treatment. The erythropoietic response was similar after 300 U/kg (59 ± 36 mL) or 100 U/kg 75 ± 24 mL). No correlation was found between RBC gain and age (r = 0.18) or baseline levels of erythropoietin (r = 0.08), hemoglobin (r = O.O6), erythrocytes (r = 0.01), reticulocytes (r = 0.01), iron (r = 0.28) and ferritin (r = 0.08). One treated patient in the experimental group was transfused with allogeneic blood (2 units) versus 5 control patients (overall 13 units) (p = 0.06). Conclusion: Preoperative treatment with r-HuEPO improved erythropoiesis and reduced allogeneic transfusions in anemic cancer patients. No significant difference in RBC gains was noted between r-HuEPO administration at 300 U/kg and r-HuEPO administration at 100 U/kg. This result suggests a possible dose reduction for future trials.
KW - Anemia
KW - Blood transfusion
KW - Cancer
KW - Cost/benefit analysis
KW - Erythropoiesis
KW - Erythropoietin
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=0030960205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030960205&partnerID=8YFLogxK
M3 - Article
C2 - 9222672
AN - SCOPUS:0030960205
VL - 44
SP - 685
EP - 690
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 15
ER -